Short-term intravenous fish oil and pediatric intestinal failure associated liver disease: 3-year follow-up on liver function and nutrition

Kara Calkins; Allison Lowe; Stephen B Shew; James C Y Dunn; Laurie Reyen; Douglas G Farmer; Sherin U Devaskar; Robert Venick

doi:10.1016/j.jpedsurg.2012.10.044

Short-term intravenous fish oil and pediatric intestinal failure associated liver disease: 3-year follow-up on liver function and nutrition

J Pediatr Surg. 2013 Jan;48(1):228-32. doi: 10.1016/j.jpedsurg.2012.10.044.

Authors

Kara Calkins¹, Allison Lowe, Stephen B Shew, James C Y Dunn, Laurie Reyen, Douglas G Farmer, Sherin U Devaskar, Robert Venick

Affiliation

¹ Department of Pediatrics, Division of Neonatology and Developmental Biology, David Geffen School of Medicine, University of California, Los Angeles, Mattel Children's Hospital, Los Angeles, CA 90095, USA. [email protected]

Abstract

Intravenous fish oil (FO) has changed the management of intestinal failure associated liver disease (IFALD). This report describes two IFALD patients who received FO for 5 and 10 months, respectively and reports on their 3-year follow-up.

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Fat Emulsions, Intravenous / therapeutic use*
Female
Fish Oils / therapeutic use*
Follow-Up Studies
Hepatic Insufficiency / diagnosis
Hepatic Insufficiency / etiology
Hepatic Insufficiency / therapy*
Humans
Infant, Newborn
Liver Function Tests
Parenteral Nutrition / methods*
Short Bowel Syndrome / complications*
Short Bowel Syndrome / therapy

Substances

Fat Emulsions, Intravenous
Fish Oils

Abstract

Publication types

MeSH terms

Substances

Grants and funding